Risk factor control in patients with Type 2 diabetes and coronary heart disease: Findings from the Swedish National Diabetes Register (NDR)

Diabetic Medicine

Volumn 26, Issue 1, 2009, Pages 53-60

  Gudbjornsdottir S ^b   Eeg Olofsson, K ^b   Cederholm, J ^c   Zethelius, B ^c   Eliasson, B ^b   Nilsson, P M ^a  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Coronary heart disease; Diabetes mellitus; Hyperlipidaemia; Hypertension; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; SMOKING; WAIST CIRCUMFERENCE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SECONDARY PREVENTION; SWEDEN;

EID: 58149291851     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02633.x     Document Type: Article

References (30)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444.
2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006 368 : 29 36.
3. Lenzen M, Rydén L, Ohrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006 27 : 2969 2974.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 865.
6. Patel A ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 370 : 829 840.
7. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 : 685 696.
8. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 2007 28 : 1925 1927.
9. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J et al. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 371 : 117 125.
10. Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B, for the Steering Committee of the National Diabetes Register. The National Diabetes Register in Sweden. An implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003 26 : 1270 1276.
11. Nilsson PM, Gudbjörnsdottir S, Eliasson B, Cederholm J, for the Steering Committee of the National Diabetes Register, Sweden. Hypertension in diabetes - trends in control and relation to macrovascular morbidity in repeated national surveys from Sweden. J Hum Hypertens 2003 17 : 37 44.
12. 1c values and microalbuminuria in patients with diabetes - data from the National Diabetes Register in Sweden. Diabetes Metab 2004 30 : 261 268.
13. Cederholm J, Eliasson B, Nilsson PM, Weiss L, Gudbjörnsdottir S, for the Steering Committee of the Swedish National Diabetes Register. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract 2005 67 : 258 266.
14. Eliasson B, Cederholm J, Nilsson PM, Gudbjörnsdottir S, for the Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996-2003. Diabet Med 2005 22 : 1420 1426.
15. Ridderstråle M, Eliasson B, Cederholm J, Nilsson PM, Gudbjörnsdottir S. Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish national diabetes register. J Intern Med 2005 259 : 314 322.
16. 1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004 1 : 166 174.
17. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al. Task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 28 : 88 136.
18. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007 115 : 114 126.
19. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Rosselin GE et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989 32 : 300 304.
20. Laws A, Reaven G. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992 1 : 25 30.
21. Fossum E, Gleim GW, Kjeldsen SE, Julius S, Dahlöf B et al. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. J Intern Med 2007 262 : 439 448.
22. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003 254 : 45 66.
23. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006 29 : 531 537.
24. Pyörälä K, Lehto S, De Bacquer D, De Sutter J, Sans S, Keil U et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from EUROASPIRE I and II surveys. Diabetologia 2004 47 : 1257 1265.
25. Anselmino M, Bartnik M, Malmberg K, Rydén L, on behalf of the Euro Heart Survey. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart. Eur J Cardiovasc Prev Rehab 2007 14 : 28 36.
26. EUROASPIRE I and II Group, European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001 357 : 995 1001.
27. Norhammar A, Malmberg K, Rydén L, Tornvall P, Stenestrand U, Wallentin L et al. Under utilization of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 2003 24 : 838 844.
28. Norhammar A, Lindbäck J, Rydén L, Wallentin L, Stenestrand U, Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 2007 93 : 1577 1583.
29. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, Isacsson SO et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 2000 16 : 235 243.
30. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 358 : 580 591.